Focused On-demand Library for Low density lipoprotein receptor adapter protein 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q5SW96

UPID:
ARH_HUMAN

ALTERNATIVE NAMES:
Autosomal recessive hypercholesterolemia protein

ALTERNATIVE UPACC:
Q5SW96; A2BHI5; Q6TQS9; Q8N2Y0; Q9UFI9

BACKGROUND:
The Low density lipoprotein receptor adapter protein 1, known for its alternative name, autosomal recessive hypercholesterolemia protein, is essential in the endocytosis process of LDL receptors in polarized cells. It ensures the LDL binding and internalization, playing a significant role in lipid homeostasis and cholesterol management within the body.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Low density lipoprotein receptor adapter protein 1 could open doors to potential therapeutic strategies. Its involvement in familial hypercholesterolemia, type 4, underscores its importance in lipid metabolism disorders, offering a promising avenue for developing treatments aimed at reducing LDL cholesterol levels and preventing cardiovascular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 960 of 8789